NICE backs use of Roche’s Gazyvaro with bendustamine
The treatment could benefit 500 people with follicular lymphoma
Read More
Tag: Gazyvaro
AbbVie, Roche present positive Venclyxto results at ASCO
Venclyxto is a first-in-class targeted medicine designed to selectively bind and inhibit the B-cell lymphoma-2 protein.
Read More
Four new medicines available via NHS Scotland
The Scottish Medicines Consortium has cleared funds for use of four new medicines by NHS Scotland, including Sanofi’s biologic Dupixent for dermatitis.
Read More
Roche’s Gazyvaro gets NICE nod for high-risk lymphoma patients
Cost regulators for NHS treatments in England and Wales have now recommended funding for Roche’s Gazyvaro for some patients with untreated follicular lymphoma, after the submission of new data by the company.
Read More
SMC bars four medicines from NHS
The Scottish Medicines Consortium has rejected NHS funding for four new therapies, including Bristol-Myers Squibb and Roche’s respective cancer medicines Opdivo and Gazyvaro.
Read More
NICE rejects first-line use of Roche’s Gazyvaro
The National Institute for Health and Care Excellence has turned down first-line use of Roche’s Gazyvaro in patients with untreated advanced follicular lymphoma on the NHS in England and Wales.
Read More
NICE backs Roche’s Gazyvaro for follicular lymphoma
The National Institute for Health and Care Excellence has issued final draft guidance recommending that use of Roche’s Gazyvaro to treat follicular lymphoma be funded for NHS use via the Cancer Drug Fund.
Read More
SMC welcomes Roche’s Gazyvaro but rejects Shire’s Onivyde
Patients with follicular lymphoma in Scotland have gained a new treatment option for the condition after the Scottish Medicines Consortium (SMC) published advice accepting Roche’s Gazyvaro for routine use by NHS Scotland. On the downside, funding for Shire’s Onivyde to treat pancreatic cancer was rejected.
Read More
Roche’s Gazyva fails to hit target in lymphoma trial
Roche’s new blood cancer drug Gazyva has failed to show significant improvements versus veteran therapy MabThera/Rituxan in patients with previously untreated diffuse large B-cell lymphoma, marking a setback in plans to protect sales from biosimilar competition.
Read More
Roche’s Gazyvaro cleared in EU for follicular lymphoma
Roche has won European approval for cancer drug Gazyvaro as a treatment for some patients with previously treated follicular lymphoma, the most common type of indolent non-Hodgkin’s lymphoma.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
